SOPH insider buying and SEC filings, explained
SOPHiA GENETICS SA · CIK 1840706
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$99K
Insiders who bought
1
Sold (not marked 10b5-1)
$6K
Planned sales (10b5-1)
$5.2M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 12, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $7.26 ($36K), marked as a 10b5-1 plan trade. Holdings down 2% to 195,993 shares. | SEC filing Filed Oct 14, 2026, 4:04 PM ET |
| Oct 13, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 4,000 shares at about $7.18 ($29K), marked as a 10b5-1 plan trade. Holdings down 1% to 541,493 shares. | SEC filing Filed Oct 14, 2026, 4:03 PM ET |
| Oct 12, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 8,500 shares at about $7.26 ($62K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,387,150 shares. | SEC filing Filed Oct 14, 2026, 4:02 PM ET |
| Oct 5, 2026 | Planned (10b5-1) | Well Daan Van (Chief Legal Officer) sold 6,168 shares at about $8.12 ($50K), marked as a 10b5-1 plan trade. Holdings down 2% to 332,716 shares. | SEC filing Filed Oct 7, 2026, 4:04 PM ET |
| Oct 5, 2026 | Planned (10b5-1) | Manuela Valente (Chief People Officer) sold 4,240 shares at about $8.13 ($34K), marked as a 10b5-1 plan trade. Holdings down 2% to 206,210 shares. | SEC filing Filed Oct 7, 2026, 4:04 PM ET |
| Oct 5, 2026 | Planned (10b5-1) | Abhimanyu Verma (Chief Technology Officer) sold 5,284 shares at about $8.12 ($43K), marked as a 10b5-1 plan trade. Holdings down 3% to 166,887 shares. | SEC filing Filed Oct 7, 2026, 4:04 PM ET |
| Oct 5, 2026 | Sale | Kevin Puylaert (Chief Sales Officer) sold 216 shares at about $8.04 ($2K). Holdings down <1% to 147,732 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 7, 2026, 4:04 PM ET |
| Oct 5, 2026 | Planned (10b5-1) | George Cardoza (CFO) sold 1,592 shares at about $8.10 ($13K), marked as a 10b5-1 plan trade. Holdings down 1% to 306,726 shares. | SEC filing Filed Oct 7, 2026, 4:04 PM ET |
| Oct 5, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 7,394 shares at about $8.13 ($60K), marked as a 10b5-1 plan trade. Holdings down 4% to 200,993 shares. | SEC filing Filed Oct 7, 2026, 4:04 PM ET |
| Oct 5, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 40,172 shares at about $8.13 ($327K), marked as a 10b5-1 plan trade. Holdings down 1% to 3,395,650 shares. | SEC filing Filed Oct 7, 2026, 4:04 PM ET |
| Oct 5, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 7,394 shares at about $8.12 ($60K), marked as a 10b5-1 plan trade. Holdings down 1% to 545,493 shares. | SEC filing Filed Oct 7, 2026, 4:04 PM ET |
| Oct 5, 2026 | Planned (10b5-1) | Ross Muken (CEO and Director) sold 9,838 shares at about $8.13 ($80K), marked as a 10b5-1 plan trade. Holdings down 1% to 660,391 shares. | SEC filing Filed Oct 7, 2026, 4:03 PM ET |
| Sep 21, 2026 | Planned (10b5-1) | George Cardoza (CFO) sold 774 shares at $8.33 ($6K), marked as a 10b5-1 plan trade. Holdings down <1% to 308,318 shares. | SEC filing Filed Sep 22, 2026 |
| Sep 21, 2026 | Planned (10b5-1) | Ross Muken (CEO and Director) sold 422 shares at $8.33 ($4K), marked as a 10b5-1 plan trade. Holdings down <1% to 670,229 shares. | SEC filing Filed Sep 22, 2026 |
| Sep 14, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $7.88 ($39K), marked as a 10b5-1 plan trade. Holdings down 2% to 208,387 shares. | SEC filing Filed Sep 16, 2026 |
| Sep 14, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 4,000 shares at about $7.88 ($32K), marked as a 10b5-1 plan trade. Holdings down 1% to 552,887 shares. | SEC filing Filed Sep 16, 2026 |
| Sep 11, 2026 | Planned (10b5-1) | Well Daan Van (Chief Legal Officer) sold 6,168 shares at about $7.63 ($47K), marked as a 10b5-1 plan trade. Holdings down 2% to 338,884 shares. | SEC filing Filed Sep 14, 2026 |
| Sep 10, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 8,500 shares at about $7.66 ($65K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,435,822 shares. | SEC filing Filed Sep 14, 2026 |
| Sep 8, 2026 | Planned (10b5-1) | Kathy L. Hibbs (Director) sold 6,250 shares at about $8.13 ($51K), marked as a 10b5-1 plan trade. Holdings down 6% to 96,992 shares. | SEC filing Filed Sep 10, 2026 |
| Aug 27, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 10,000 shares at about $8.91 ($89K), marked as a 10b5-1 plan trade. Holdings down 2% to 556,887 shares. | SEC filing Filed Aug 31, 2026 |
| Aug 25, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $8.68 ($43K), marked as a 10b5-1 plan trade. Holdings down 2% to 213,387 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 25, 2026 | Planned (10b5-1) | Kathy L. Hibbs (Director) sold 6,250 shares at about $8.68 ($54K), marked as a 10b5-1 plan trade. Holdings down 6% to 103,242 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 19–24, 2026 | Planned (10b5-1) | Abhimanyu Verma (Chief Technology Officer) sold 10,000 shares between Aug 19 and Aug 24 at about $8.50 ($85K), marked as a 10b5-1 plan trade. Holdings down 5% to 172,171 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 19, 2026 | Planned (10b5-1) | Manuela Valente (Chief People Officer) sold 10,000 shares at about $7.94 ($79K), marked as a 10b5-1 plan trade. Holdings down 5% to 210,450 shares. | SEC filing Filed Aug 21, 2026 |
| Aug 19–21, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 20,000 shares between Aug 19 and Aug 21 at about $8.17 ($163K), marked as a 10b5-1 plan trade. Holdings down 3% to 566,887 shares. | SEC filing Filed Aug 21, 2026 |
| Aug 13, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 4,000 shares at about $7.52 ($30K), marked as a 10b5-1 plan trade. Holdings down 1% to 586,887 shares. | SEC filing Filed Aug 14, 2026 |
| Aug 12, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $7.52 ($38K), marked as a 10b5-1 plan trade. Holdings down 2% to 218,387 shares. | SEC filing Filed Aug 14, 2026 |
| Aug 7, 2026 | Planned (10b5-1) | Abhimanyu Verma (Chief Technology Officer) sold 5,000 shares at $7.60 ($38K), marked as a 10b5-1 plan trade. Holdings down 3% to 182,171 shares. | SEC filing Filed Aug 10, 2026 |
| Aug 7–10, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 28,500 shares between Aug 7 and Aug 10 at about $7.34 ($209K), marked as a 10b5-1 plan trade. Holdings down 1% to 3,444,322 shares. | SEC filing Filed Aug 10, 2026 |
| Aug 5–7, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 20,000 shares between Aug 5 and Aug 7 at about $7.25 ($145K), marked as a 10b5-1 plan trade. Holdings down 3% to 590,887 shares. | SEC filing Filed Aug 7, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Abhimanyu Verma (Chief Technology Officer) sold 5,000 shares at about $6.95 ($35K), marked as a 10b5-1 plan trade. Holdings down 3% to 187,171 shares. | SEC filing Filed Aug 5, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 20,000 shares at about $6.92 ($138K), marked as a 10b5-1 plan trade. Holdings down 1% to 3,472,822 shares. | SEC filing Filed Aug 5, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 10,000 shares at about $6.92 ($69K), marked as a 10b5-1 plan trade. Holdings down 2% to 600,887 shares. | SEC filing Filed Aug 5, 2026 |
| Jul 27, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $5.66 ($28K), marked as a 10b5-1 plan trade. Holdings down 2% to 223,387 shares. | SEC filing Filed Jul 28, 2026 |
| Jul 20–21, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 44,381 shares between Jul 20 and Jul 21 at about $6.44 ($286K), marked as a 10b5-1 plan trade. Holdings down 1% to 3,492,822 shares. | SEC filing Filed Jul 22, 2026 |
| Jul 13, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $5.70 ($29K), marked as a 10b5-1 plan trade. Holdings down 2% to 228,387 shares. | SEC filing Filed Jul 14, 2026 |
| Jul 13, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 4,000 shares at about $5.70 ($23K), marked as a 10b5-1 plan trade. Holdings down 1% to 610,887 shares. | SEC filing Filed Jul 14, 2026 |
| Jul 10, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 8,500 shares at about $5.62 ($48K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,532,622 shares. | SEC filing Filed Jul 14, 2026 |
| Jul 7, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 17,685 shares at $5.28 ($93K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,541,122 shares. | SEC filing Filed Jul 8, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | George Cardoza (CFO) sold 1,592 shares at about $5.29 ($8K), marked as a 10b5-1 plan trade. Holdings down 1% to 309,092 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Manuela Valente (Chief People Officer) sold 4,241 shares at about $5.05 ($21K), marked as a 10b5-1 plan trade. Holdings down 2% to 210,450 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Abhimanyu Verma (Chief Technology Officer) sold 5,285 shares at about $5.10 ($27K), marked as a 10b5-1 plan trade. Holdings down 3% to 192,171 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 7,393 shares at about $5.17 ($38K), marked as a 10b5-1 plan trade. Holdings down 1% to 614,887 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Ross Muken (CEO and Director) sold 9,838 shares at about $5.22 ($51K), marked as a 10b5-1 plan trade. Holdings down 1% to 670,651 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 6, 2026 | Sale | Kevin Puylaert (Chief Sales Officer) sold 216 shares at about $5.04 ($1K). Holdings down <1% to 147,948 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 7, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 7,393 shares at about $5.16 ($38K), marked as a 10b5-1 plan trade. Holdings down 3% to 233,387 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 22,486 shares at about $5.26 ($118K), marked as a 10b5-1 plan trade. Holdings down 1% to 3,558,807 shares. | SEC filing Filed Jul 7, 2026 |
| Jun 29–30, 2026 | Planned (10b5-1) | Jurgi Camblong (Chair and Director) sold 83,679 shares between Jun 29 and Jun 30 at about $6.05 ($507K), marked as a 10b5-1 plan trade. Holdings down 2% to 3,581,293 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 25–26, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 51,442 shares between Jun 25 and Jun 26 at about $5.80 ($298K), marked as a 10b5-1 plan trade. Holdings down 1% to 3,601,493 shares. | SEC filing Filed Jun 29, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Abhimanyu Verma (Chief Technology Officer) sold 6,944 shares at about $5.51 ($38K), marked as a 10b5-1 plan trade. Holdings down 3% to 197,456 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $5.50 ($28K), marked as a 10b5-1 plan trade. Holdings down 2% to 240,780 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | George Cardoza (CFO) sold 774 shares at about $5.38 ($4K), marked as a 10b5-1 plan trade. Holdings down <1% to 310,684 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Ross Muken (President / COO) sold 422 shares at about $5.38 ($2K), marked as a 10b5-1 plan trade. Holdings down <1% to 680,489 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 4,000 shares at about $5.01 ($20K), marked as a 10b5-1 plan trade. Holdings down 1% to 622,280 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $4.95 ($25K), marked as a 10b5-1 plan trade. Holdings down 2% to 245,780 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 10, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 8,500 shares at about $5.24 ($45K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,620,995 shares. | SEC filing Filed Jun 11, 2026 |
| Jun 5, 2026 | Purchase (code P) | George Cardoza (CFO) bought 20,000 shares at $4.95 ($99K), reported as a purchase (code P). Holdings up 7% to 311,458 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 5, 2026 |
| May 26, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $4.95 ($25K), marked as a 10b5-1 plan trade. Holdings down 2% to 250,780 shares. | SEC filing Filed Jun 1, 2026 |
| May 19, 2026 | Planned (10b5-1) | Ross Muken (President / COO) sold 761 shares at about $4.60 ($4K), marked as a 10b5-1 plan trade. Holdings down <1% to 680,911 shares. | SEC filing Filed May 20, 2026 |
| May 19, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 608 shares at about $4.60 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 626,280 shares. | SEC filing Filed May 20, 2026 |
| May 19, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 4,486 shares at about $4.60 ($21K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,629,495 shares. | SEC filing Filed May 20, 2026 |
| May 19, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 608 shares at about $4.61 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 255,780 shares. | SEC filing Filed May 20, 2026 |
| May 19, 2026 | Planned (10b5-1) | Well Daan Van (Chief Legal Officer) sold 684 shares at about $4.60 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 345,052 shares. | SEC filing Filed May 20, 2026 |
| May 19, 2026 | Planned (10b5-1) | Manuela Valente (Chief People Officer) sold 380 shares at about $4.60 ($2K), marked as a 10b5-1 plan trade. Holdings down <1% to 214,691 shares. | SEC filing Filed May 20, 2026 |
| May 19, 2026 | Sale | Kevin Puylaert (Chief Sales Officer) sold 33 shares at $4.54 ($150). Holdings down <1% to 148,164 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| May 13, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 4,000 shares at about $4.54 ($18K), marked as a 10b5-1 plan trade. Holdings down 1% to 626,888 shares. | SEC filing Filed May 14, 2026 |
| May 12, 2026 | Planned (10b5-1) | Kathy L. Hibbs (Director) sold 7,508 shares at about $4.67 ($35K), marked as a 10b5-1 plan trade. Holdings down 8% to 89,768 shares. | SEC filing Filed May 13, 2026 |
| May 12, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $4.67 ($23K), marked as a 10b5-1 plan trade. Holdings down 2% to 256,388 shares. | SEC filing Filed May 13, 2026 |
| May 11, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 8,500 shares at about $5.09 ($43K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,633,981 shares. | SEC filing Filed May 12, 2026 |
| Apr 27, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,000 shares at about $4.82 ($24K), marked as a 10b5-1 plan trade. Holdings down 2% to 261,388 shares. | SEC filing Filed Apr 28, 2026 |
| Apr 20, 2026 | Planned (10b5-1) | Manuela Valente (Chief People Officer) sold 380 shares at about $5.20 ($2K), marked as a 10b5-1 plan trade. Holdings down <1% to 215,071 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 20, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 608 shares at about $5.21 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 630,888 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 20, 2026 | Planned (10b5-1) | Well Daan Van (Chief Legal Officer) sold 684 shares at about $5.20 ($4K), marked as a 10b5-1 plan trade. Holdings down <1% to 345,736 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 20, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 4,486 shares at about $5.21 ($23K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,642,481 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 20, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 608 shares at about $5.20 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 266,388 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 20, 2026 | Planned (10b5-1) | Ross Muken (President / COO) sold 760 shares at about $5.20 ($4K), marked as a 10b5-1 plan trade. Holdings down <1% to 681,672 shares. | SEC filing Filed Apr 21, 2026 |
| Apr 20, 2026 | Sale | Kevin Puylaert (Chief Sales Officer) sold 33 shares at $5.08 ($168). Holdings down <1% to 148,197 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 21, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 600 shares at about $4.97 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 631,496 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 14–15, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 60,602 shares between Apr 14 and Apr 15 at about $4.97 ($301K), marked as a 10b5-1 plan trade. Holdings down 2% to 3,646,967 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 1,600 shares at about $4.96 ($8K), marked as a 10b5-1 plan trade. Holdings down 1% to 266,996 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Ross Muken (President / COO) sold 2,800 shares at about $4.96 ($14K), marked as a 10b5-1 plan trade. Holdings down <1% to 682,432 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 10, 2026 | Planned (10b5-1) | Well Daan Van (Chief Legal Officer) sold 2,400 shares at about $4.67 ($11K), marked as a 10b5-1 plan trade. Holdings down 1% to 346,420 shares. | SEC filing Filed Apr 14, 2026 |
| Apr 10–13, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 8,120 shares between Apr 10 and Apr 13 at about $4.72 ($38K), marked as a 10b5-1 plan trade. Holdings down 1% to 632,096 shares. | SEC filing Filed Apr 14, 2026 |
| Apr 10–13, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 16,631 shares between Apr 10 and Apr 13 at about $4.73 ($79K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,707,569 shares. | SEC filing Filed Apr 14, 2026 |
| Apr 10–13, 2026 | Planned (10b5-1) | Ross Muken (President / COO) sold 8,129 shares between Apr 10 and Apr 13 at about $4.73 ($38K), marked as a 10b5-1 plan trade. Holdings down 1% to 685,232 shares. | SEC filing Filed Apr 14, 2026 |
| Apr 10–13, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 8,125 shares between Apr 10 and Apr 13 at about $4.72 ($38K), marked as a 10b5-1 plan trade. Holdings down 3% to 268,596 shares. | SEC filing Filed Apr 14, 2026 |
| Apr 8–9, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 4,750 shares between Apr 8 and Apr 9 at about $4.80 ($23K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,724,200 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 8–9, 2026 | Planned (10b5-1) | Ross Muken (President / COO) sold 4,736 shares between Apr 8 and Apr 9 at about $4.80 ($23K), marked as a 10b5-1 plan trade. Holdings down 1% to 693,361 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 8–9, 2026 | Planned (10b5-1) | Zhenyu Xu (Chief Scientific Officer) sold 4,736 shares between Apr 8 and Apr 9 at about $4.80 ($23K), marked as a 10b5-1 plan trade. Holdings down 1% to 640,216 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 8–9, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 4,731 shares between Apr 8 and Apr 9 at about $4.80 ($23K), marked as a 10b5-1 plan trade. Holdings down 2% to 276,721 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 8, 2026 | Planned (10b5-1) | Manuela Valente (Chief People Officer) sold 3,824 shares at about $4.85 ($19K), marked as a 10b5-1 plan trade. Holdings down 2% to 215,451 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 8–9, 2026 | Planned (10b5-1) | Well Daan Van (Chief Legal Officer) sold 4,849 shares between Apr 8 and Apr 9 at about $4.80 ($23K), marked as a 10b5-1 plan trade. Holdings down 1% to 348,820 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 8, 2026 | Planned (10b5-1) | George Cardoza (CFO) sold 1,403 shares at about $4.85 ($7K), marked as a 10b5-1 plan trade. Holdings down <1% to 291,458 shares. | SEC filing Filed Apr 10, 2026 |
| Apr 6–7, 2026 | Planned (10b5-1) | Philippe Menu (Chief Medical Officer) sold 5,100 shares between Apr 6 and Apr 7 at about $4.86 ($25K), marked as a 10b5-1 plan trade. Holdings down 2% to 281,452 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 6, 2026 | Sale | Kevin Puylaert (Chief Sales Officer) sold 624 shares at about $4.86 ($3K). Holdings down <1% to 148,230 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 8, 2026 |
| Apr 6–7, 2026 | Planned (10b5-1) | Well Daan Van (Chief Legal Officer) sold 5,105 shares between Apr 6 and Apr 7 at about $4.86 ($25K), marked as a 10b5-1 plan trade. Holdings down 1% to 353,669 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 6–7, 2026 | Planned (10b5-1) | Ross Muken (President / COO) sold 5,024 shares between Apr 6 and Apr 7 at about $4.86 ($24K), marked as a 10b5-1 plan trade. Holdings down 1% to 698,097 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 6–7, 2026 | Planned (10b5-1) | Jurgi Camblong (CEO and Director) sold 5,100 shares between Apr 6 and Apr 7 at about $4.85 ($25K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,728,950 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 6–7, 2026 | Planned (10b5-1) | George Cardoza (CFO) sold 4,933 shares between Apr 6 and Apr 7 at about $4.86 ($24K), marked as a 10b5-1 plan trade. Holdings down 2% to 292,861 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 6–7, 2026 | Planned (10b5-1) | Manuela Valente (Chief People Officer) sold 4,973 shares between Apr 6 and Apr 7 at about $4.86 ($24K), marked as a 10b5-1 plan trade. Holdings down 2% to 219,275 shares. | SEC filing Filed Apr 8, 2026 |
Showing the latest 100 transactions.
19 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SOPH in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.